Serum Angiotensin II Level in Chronic Hepatitis C Patients Who Achieved Sustained Virologic Response after Direct Antiviral Agent Therapy
Study ID: TCTR20161025001
Current status: Enrolling by invitation
Last Updated: August 22, 2017
Tracking Information
Date of Registration in Primary Registry: October 21, 2016
Date of First Enrollment: October 31, 2016 (Actual)
Target Sample Size: 40
Last Updated Date: August 22, 2017
Primary Outcome(s):
  • Outcome name: Serum Angiotensin II Level
       Metric/method of measurement: ELISA
       Time point: Start treatment and sustained virologic response
       Safety Issue?: No


  • Key Secondary Outcomes:
  • Outcome name: Serum TGF-beta 1, TIMP-1, and MMP 9 Levels
       Metric/method of measurement: ELISA
       Time point: Start treatment and sustained virologic response
       Safety Issue?: No


  • Descriptive Information
    Public Title: Serum Angiotensin II Level in Chronic Hepatitis C Patients Who Achieved Sustained Virologic Response after Direct Antiviral Agent Therapy
    Scientific Title: Serum Angiotensin II Level in Chronic Hepatitis C Patients Who Achieved Sustained Virologic Response after Direct Antiviral Agent Therapy
    Brief Summary:
    Detailed Description:
    Study Design: Allocation: Non-randomized
    Control: N/A
    Study Endpoint Classification: N/A
    Intervention Model: Single Group
    Number of Groups: 1
    Masking: (Masked Roles: )
    Primary Purpose: Basic Science
    Study Phase: N/A
    Health Condition(s) or Problem(s) Studied: Chronic hepatitis C Patients who Achieved Sustained Virologic Response after Direct Antiviral Agent Therapy
    Study Groups:
  • Group: 1
  • Group Name: HCVDAA
    Descriptions: Chronic hepatitis C patients treated with direct antiviral therapy
    Recruitment Information
    Recruitment Status: Enrolling by invitation
    Estimated Enrollment: 40
    Study Start Date (First enrollment): October 31, 2016
    Primary Completion Date: December 31, 2017
    Inclusion Criteria:
    Inclusion Criteria
    Gender: Both
    Age Limit: Minimum 18 Years : Maximum 0 N/A (No limit)
    Age >/= 18 years old
    Chronic hepatitis C infection
    Direct antiviral agent therapy
    Exclusion Criteria
    Hepatitis B coinfection
    HIV coinfection
    Other known etiology of liver disease e g alcoholism autoimmune hepatitis biliary cirrhosis congestive hepatopathy congenital or hereditary liver disease infiltrative liver disease
    Decompensated cirrhosis
    Hepatocellular carcinoma
    Immunosuppressive agent used
    Renin inhibitor angiotensin converting enzyme inhibitor angiotensin receptor blocker or aldosterone antagonist used
    Diuretic agent used
    Oral contraceptive therapy
    Renin secreting tumor
    Renal hypertension or malignant hypertension BP 220 120 mmHg
    Chronic kidney disease eGFR 60 ml min m2
    Incomplete treatment
    Who dose not achieve sustained virologic response

    Accept Healthy Volunteers: No
    Countries of Recruitment Thailand
    Contact for Public Queries:
    Contact for Public Query's Name: Nicha Teeratorn
    Phone: 0898588947
    Email: nicha.teeratorn@gmail.com
    Postal Address: Division of Gastroenterology, King Chulalongkorn Memorial Hospital, Patumwan
    State/Province: Bangkok        Postal Code: 10330
    Country: Thailand
    Administrative Information
    Primary Registry Site: Thai Clinical Trials Registry
    Trial Identification Number: TCTR20161025001
    Secondary Identifying Numbers: Nil known
    Source(s) of Monetary or Material Supports: N/A
    Study Primary Sponsor: N/A
    Study Secondary Sponsor: 1.) N/A
    Contact for Scientific Queries:
    Contact for Scientific Query's Name: Nicha Teeratorn
    Phone: 0898588947
    Email: nicha.teeratorn@gmail.com
    Postal Address: Division of Gastroenterology, King Chulalongkorn Memorial Hospital, Patumwan
    State/Province: Bangkok        Postal Code: 10330
    Country: Thailand
    Track changes

    Copyright  © 2009. Medical Research Foundation, Thailand. All Rights Reserved.